Novartis
NVS
1,561 hedge funds and large institutions have $19.1B invested in Novartis in 2026 Q3 according to their latest regulatory filings, with 105 funds opening new positions, 468 increasing their positions, 635 reducing their positions, and 141 closing their positions.
2% more capital inflows, than outflows
Capital inflows: $1.99B | Capital outflows: $1.95B
0.12% less ownership
Funds ownership: 7.15% → 7.03% (-0.12%)
5% less funds holding
Funds holding: 1,635 → 1,561 (-74)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
26% less first-time investments, than exits
New positions opened: 105 | Existing positions closed: 141
26% less repeat investments, than reductions
Existing positions increased: 468 | Existing positions reduced: 635
50% less call options, than puts
Call options by funds: $571M | Put options by funds: $1.15B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$196M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$188M |
| 3 |
LMR Partners
London,
United Kingdom
|
+$116M |
| 4 |
ClearBridge Investments
New York
|
+$110M |
| 5 |
Barclays
London,
United Kingdom
|
+$73.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$319M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$270M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$92M |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$91.6M |
| 5 |
Holocene Advisors
New York
|
-$85.2M |
NVS Hedge Fund Activity: Q3 2026 in Review
1,561 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2026, worth a combined $19.1B — down 11% from $21.4B a quarter earlier.
Sellers outnumbered buyers: 141 funds closed out of NVS and 105 opened new positions — a net loss of 36 holders — while 635 trimmed existing stakes and 468 added.
The largest buyer was Citadel Advisors, adding an estimated $196M. The largest seller was GQG Partners, cutting an estimated $319M.
- 1,561 institutional investors held Novartis (NVS) as of Q3 2026, down from 1,635 in Q2 2026.
- Funds reported $19.1B of Novartis stock for Q3 2026, down 11% quarter-over-quarter.
- 105 funds opened new Novartis positions in Q3 2026 and 141 closed out, a net change of -36 holders.
- The largest Novartis buyer in Q3 2026 was Citadel Advisors, an estimated $196M added.
- The largest Novartis seller in Q3 2026 was GQG Partners, an estimated $319M sold.
Based on aggregated 13F filings for Q3 2026.